SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2M
Q2 2023
Positions
79
Filings on Record
27
2019–present window
Filed
Aug 14, 2023
original filing

Summary

Boxer Capital, LLC reported $2M in U.S.-listed holdings across 79 positions for Q2 2023.

Its largest position, RETAEUR, represents 6.8% of the portfolio.

Compared with Q1 2023, the fund opened 9 new positions and exited 5.

Portfolio Metrics

Turnover
+19.9%
vs prior filed quarter
Top-10 Concentration
+46.0%
share of reported value
Largest Position
+6.8%
Reata Pharmaceuticals
New / Exited
9 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 83.9%Other: 8.2%ADR: 7.9%Equity WRT: 0.0%
  • Common Stock · 83.9% · $2M
  • Other · 8.2% · $177,526
  • ADR · 7.9% · $170,513
  • Equity WRT · 0.0% · $48

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IMGNEURImmunoGen IncNEW+2.96M2.96M+$55,874$55,874
Karuna Therapeutics IncNEW+250.0K250.0K+$54,213$54,213
LEGNLegend Biotech CorpNEW+600.0K600.0K+$41,418$41,418
ARGXArgenx SENEW+75.0K75.0K+$29,230$29,230
MDGLMadrigal Pharmaceuticals IncNEW+100.0K100.0K+$23,100$23,100
ZNTLZentalis Pharmaceuticals IncNEW+450.0K450.0K+$12,695$12,695
GONGeron CorpNEW+3.00M3.00M+$9,630$9,630
Mersana Therapeutics IncNEW+1.00M1.00M+$3,290$3,290

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RETAEURReata Pharmaceuticals Inchistory →CL A6.76%$145,8031.43M
2APLSUSDApellis Pharmaceuticals Inchistory →COM6.66%$143,5741.58M
3RVMDRevolution Medicines Inchistory →COM5.81%$125,3044.68M
4TYRATyra Biosciences Inchistory →COM5.09%$109,8166.45M
5SWTXUSDSpringworks Therapeutics Inchistory →COM4.16%$89,7133.42M
6ONCBeiGene Ltdhistory →SPONSORED ADR4.13%$89,150500.0K
7AKROAkero Therapeutics Inchistory →COM3.63%$78,2871.68M
8MRTXEURMirati Therapeutics Inchistory →COM3.35%$72,2602.00M
9SRPTSarepta Therapeutics Inchistory →COM3.19%$68,712600.0K
10CYTKCytokinetics Inchistory →COM NEW3.18%$68,5022.10M
11IMGNEURImmunoGen Inchistory →COM2.59%$55,8742.96M
12Karuna Therapeutics IncCOM2.51%$54,213250.0K
13IDYAIdeaya Biosciences Inchistory →COM2.40%$51,7662.20M
14SG7Sage Therapeutics Inchistory →COM2.39%$51,4401.09M
15NUVLNuvalent Inchistory →COM2.37%$51,0341.21M
16Merus N VCOM2.32%$50,0271.90M
17AMLXAmylyx Pharmaceuticals Inchistory →COM2.08%$44,9522.08M
18LEGNLegend Biotech Corphistory →SPONSORED ADS1.92%$41,418600.0K
19ETNBGBP89Bio Inchistory →COM1.85%$39,7952.10M
20RCUSArcus Biosciences Inchistory →COM1.51%$32,5411.60M
21OPHTEURIveric Bio Inchistory →COM1.51%$32,456825.0K
22VKTXViking Therapeutics Inchistory →COM1.50%$32,4202.00M
23ARGXArgenx SEhistory →SPONSORED ADR1.36%$29,23075.0K
24AM6Amicus Therapeutics Inchistory →COM1.35%$29,2022.33M
25RCKTRocket Pharmaceuticals Inchistory →COM1.35%$29,1301.47M
26AXSMAxsome Therapeutics Inchistory →COM1.33%$28,744400.0K
272662247DiTeos Therapeutics Inchistory →COM1.32%$28,5202.15M
28VTYXUSDVentyx Biosciences Inchistory →COM1.29%$27,880850.0K
29ANABAnaptysBio Inchistory →COM1.23%$26,4421.30M
30IOVAIovance Biotherapeutics Inchistory →COM1.21%$26,0843.71M
31TNGXTango Therapeutics Inchistory →COM1.10%$23,6507.12M
32MDGLMadrigal Pharmaceuticals Inchistory →COM1.07%$23,100100.0K
33XENEXenon Pharmaceuticals Inchistory →COM1.07%$23,100600.0K
34RLAYRelay Therapeutics Inchistory →COM1.06%$22,8481.82M
35Point Biopharma Global IncCOM1.05%$22,6502.50M
36EX9Exelixis Inchistory →COM1.02%$21,9771.15M
37Prothena Corp PLCSHS0.95%$20,484300.0K
38PMVPPMV Pharmaceuticals IncCOM0.92%$19,8053.16M
394XC1Kalvista Pharmaceuticals IncCOM0.69%$14,8501.65M
40ELVNEnliven Therapeutics IncCOM0.67%$14,504710.6K
41DAWNGBXDay One Biopharmaceuticals ICOM0.66%$14,2081.19M
42ORICOric Pharmaceuticals IncCOM0.62%$13,4451.73M
43ZNTLZentalis Pharmaceuticals IncCOM0.59%$12,695450.0K
44RNAGBPAvidity Biosciences IncCOM0.58%$12,4361.12M
45NRIXNurix Therapeutics IncCOM0.57%$12,2371.22M
46CGEMCullinan Oncology IncCOM0.54%$11,5571.07M
47PRLDPrelude Therapeutics IncCOM0.52%$11,2282.50M
48BDTXBlack Diamond Therapeutics ICOM0.47%$10,1752.01M
49GONGeron CorpCOM0.45%$9,6303.00M
50Ascendis Pharma A/SSPONSORED ADR0.39%$8,47995.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.